Invasive lobular breast carcinoma (ILC) is characterized by proliferative indolence and long-term latency relapses. This study aimed to identify how disseminating ILC cells control the balance between quiescence and cell cycle re-entry. In the absence of anchorage, ILC cells undergo a sustained cell cycle arrest in G0/G1 while maintaining viability. From the genes that are upregulated in anchorage independent ILC cells, we selected Inhibitor of DNA binding 2 (Id2), a mediator of cell cycle progression. Using loss-of-function experiments, we demonstrate that Id2 is essential for anchorage independent survival (anoikis resistance) in vitro and lung colonization in mice. Importantly, we find that under anchorage independent conditions, E-cadherin loss promotes expression of Id2 in multiple mouse and (organotypic) human models of ILC, an event that is caused by a direct p120-catenin/Kaiso-dependent transcriptional de-repression of the canonical Kaiso binding sequence TCCTGCNA. Conversely, stable inducible restoration of E-cadherin expression in the ILC cell line SUM44PE inhibits Id2 expression and anoikis resistance. We show evidence that Id2 accumulates in the cytosol, where it induces a sustained and CDK4/6-dependent G0/G1 cell cycle arrest through interaction with hypo-phosphorylated Rb. Finally, we find that Id2 is indeed enriched in ILC when compared to other breast cancers, and confirm cytosolic Id2 protein expression in primary ILC samples. In sum, we have linked mutational inactivation of E-cadherin to direct inhibition of cell cycle progression. Our work indicates that loss of E-cadherin and subsequent expression of Id2 drive indolence and dissemination of ILC. As such, E-cadherin and Id2 are promising candidates to stratify low and intermediate grade invasive breast cancers for the use of clinical cell cycle intervention drugs.
Clinical outcome for invasive lobular breast cancer (ILC) patients with metastatic disease is dismal once tumors stop responding to estrogen receptor antagonists . ILC has a propensity to be chemo-refractory, a feature that underpins the unsatisfactory clinical responses to standard (neo-adjuvant) treatments [1, 2]. ILC development and progression are causally related to loss of cell-cell adhesion through inactivation of adherens junctions (AJ) [3, 4], a complex founded on E-cadherin, the caretaker of epithelial integrity . It is well established that loss of E-cadherin is sufficient to drive anchorage-independence in breast cancer cells in the context of oncogenic modulation of p53  or activation of the PTEN/PI3K/AKT signaling axis [6, 7]. Because of cell-cell adhesion deficiency, ILC cells invade as single non-adhesive cells that - due to physical restriction - appear as collective invasive strands (reviewed in: ). ILC is mostly estrogen receptor (ER) positive with indolent growth characteristics, reflected by its low to intermediated grade. ILC has a tendency to present contra-lateral involvement and single cell dissemination patterns to sites such as the gastro-intestinal tract, ovaries, effusion fluids and leptomeninges . Several studies have demonstrated that ILC cells display a specific, cell-intrinsic genomic profile and biochemistry driving their solitary survival . Upon loss of AJ function and independent of ER or PI3K status, ILC cells show constitutive actomyosin contraction and AKT hyperactivation through growth factor receptor cues, which could explain their propensity for expansion in pleural and abdominal fluids (reviewed in: ). Although consensus is not complete, large and multi-parametric studies indicate that ILC patients have a worse survival after a prolonged (>15–20 years) follow-up when compared to non-ILC breast cancers [12, 13]. In sum, these traits indicate that metastatic ILC cells dampen their proliferation rate and promote cell survival pathways over extended time periods to facilitate diffuse cancer cell dissemination.
In non-cycling G0/G1 cells the retinoblastoma (Rb) tumor suppressor is hypo-phosphorylated and interacts with E2F factors to control repression of its target genes. Upon a mitotic stimulus or engagement of integrin-dependent anchorage, Rb is inactivated through cyclin-CDK-dependent phosphorylation, which disrupts its binding to the E2Fs (reviewed in: ). Rb-dependent cell cycle responses can be modulated by the inhibitor of DNA binding 2 (Id2), a helix-loop-helix (HLH) factor that acts as a regulator of E-protein function by binding and sequestering hypo- Rb through its pocket domains [15, 16]. In these studies, which were performed under anchorage-dependent two-dimensional conditions, upregulation of Id2 enhances cell proliferation and inhibits apoptosis. Nonetheless, it remained unclear how Id2-dependent control over cell cycle progression is instigated upon Id2 binding to hypo-phosphorylated Rb, and how this controls proliferation and anchorage independence of carcinoma cells.
Id2 expression has been linked to tumor initiation, growth, dissemination, and chemotherapy responses [17,18,19,20]. Increased Id2 levels in breast cancer correlate to poor prognosis , and a recent report has identified Id2 as a promoter of breast cancer colonization to the brain . Also, Id2 expression has been implicated in the maintenance of breast cancer stemness and possible control over the transition from ductal carcinoma in situ (DCIS) to invasive cancer . While Id2 controls tumor progression features, it is still unclear how its established ties to Rb-dependent cell cycle regulation affect tumor cell survival, anchorage independence, and metastasis. Importantly, the underlying mechanisms controlling Id2 expression during tumor progression are still elusive.
Here, we demonstrate that Id2 represents a key factor that promotes sustained cell cycle quiescence in human and mouse models of ILC. Our data provides a causal link from E-cadherin loss to a direct and p120/Kaiso-dependent transcriptional upregulation of Id2, which is exacerbated in the absence of cell-matrix engagement. Functionally, Id2 promotes a low proliferative indolent state in lobular breast cancer cells through inhibition of CDK4/6-Rb-dependent cell cycle progression, enabling anchorage independence and subsequent metastatic dissemination.
E-cadherin deficient anoikis resistant breast cancer cells undergo a sustained G0/G1 arrest in anchorage-independent conditions
ILC cells are resistant to anchorage-independent programmed cell death (anoikis), a hallmark that underlies their metastatic capacity in vivo (Fig. 1A; relative viability (left) and number of cells (right)) (reviewed in: ). For this study we initially used mouse ILC (mILC-1) cells, because they do not contain oncogene-addictive genetic aberrations in the RAS, RAF, BRAF or the PI3K/AKT or Rb pathways . Under anchorage-independent conditions (Sus), metastatic mILC-1 cells cease to proliferate whilst retaining approximately 75% viability for several weeks [4, 25], suggesting that these anoikis resistant cells undergo a sustained G1/G0-arrested viable state. As expected, we observe that the majority (>90%) of viable cells arrest in G0/G1 when FUCCI-2 tagged cells are cultured in suspension conditions, whereas the adherent cells asynchronously proliferate, judged by the majority of mILC-1 cells in the S/G2/M phase (green or yellow cells; relative in %; Fig. 1B, C).
Because cell cycle arrest in G0/G1 is mediated through sequestering and inhibition of E2F transcription factors by hypo-phosphorylated Rb, we assessed the phosphorylation status of Rb under anchorage-independent conditions. In accordance with the observed anchorage-independent cell cycle arrest, Rb phosphorylation shifts from the hyper-phosphorylated (inactive) form under adherent conditions to the hypo-phosphorylated (active) in anchorage-independent suspended cells (Fig. 1D). Moreover, phosphorylation of the Rb Serine residues 780 and 807/811, which relies on CyclinD-CDK4/6 and CyclinE-CDK2 complexes, is reduced after 8 h and absent after 24 h of anchorage-independence (Fig. 1D). In short, anoikis-resistant mILC-1 cells transition towards a sustained G0/G1 cell cycle arrest under anchorage-independent settings.
Id2 is upregulated during anchorage-independence to enable anoikis resistance in ILC
To identify a mechanism that unites concomitant regulation of cell cycle arrest and anoikis resistance driven by E-cadherin loss, we isolated mRNA from three anoikis resistant and ERNEG mILC cell lines cultured under anchorage-independent conditions and performed genome-wide mRNA sequencing as described previously . In conjunction with our previous results , we detected that the helix-loop-helix (HLH) factor Id2 is upregulated in suspended mILC cells (Fig. 2A). Id2 was prioritized because it is an established regulator of cancer proliferation and Rb-dependent cell cycle progression [15, 16]. Western blot analysis of mILC cell lines confirms an approximate 2 to 3-fold increase in Id2 protein levels under anchorage-independent conditions, which increases over time (Fig. 2B).
Next, we analyzed if E-cadherin is causal to the regulation of Id2 expression in ER positive human breast cancer cells. For this we compared the E-cadherin expressing MCF7 wild type (WT) cell line versus two isogenic MCF7 E-cadherin knockout (∆CDH1) clones (Fig. 2C; left panel). Furthermore, we reconstituted E-cadherin expression using a Doxycyclin (DOX)-inducible system (iCDH1) in SUM44PE, an established ILC cell line, and generated two SUM44PE::iCDH1 cell lines. (Fig. 2C; right panel and Supplementary Fig. 1). As expected, we observe that E-cadherin controls anoikis resistance. Inducible E-cadherin protein expression in SUM44PE::iCDH1 cells results in a significant reduction in anoikis resistance for both inducible clones, whereas E-cadherin loss in MCF7 induces anoikis resistance in both isogenic CDH1 cell lines (Fig. 2D). Importantly, anoikis resistance upon E-cadherin loss correlates to increased Id2 mRNA levels. MCF7::ΔCDH1 cells reveal an average approximate 3-fold increase of Id2 mRNA in suspension (Fig. 2E), whereas inducible restoration of E-cadherin expression in SUM44PE cells results in an average 3-fold downregulation of Id2 expression in suspension (Fig. 2E).
In short, our data demonstrate that E-cadherin loss causes Id2 upregulation in breast cancer cells under anchorage independent conditions.
To investigate if Id2 contributes to anchorage-independent survival (anoikis resistance), we performed Id2 knock-downs in mILC using two independent shRNAs (Supplementary Fig. 2A), which results in a 2 to 5-fold decrease in anoikis resistance (Fig. 3A, p < 0.001). Apoptosis was verified by blotting for cleaved Caspase-3 (Supplementary Fig. 2B). Comparable to the mILC cells, we show that Id2 knockdown in E-cadherin mutant human SKBR3 cells using two independent Doxycycline (DOX)-inducible shRNA sequences (Supplementary Fig. 2C) results in an approximate 50–60% decrease in anoikis resistance (Fig. 3B).
To probe the in vivo consequences of Id2-dependent anchorage-independence, we performed experimental metastasis assays. We opted for intravenous injections to effectively assess lung colonization capacity as a surrogate readout for the metastatic potential of disseminated cells, because we aimed to uncouple dependency of distant colonization from primary tumor growth. These in vivo assays demonstrate that Id2 knockdown fully prevents lung colonization compared to controls (0/6 versus 7/8 mice, p < 0.0001; Fig. 3C, D), indicating that Id2 is required for metastatic colonization of E-cadherin deficient breast cancer cells.
Next, we analyzed if expression of Id2 in E-cadherin positive cells is sufficient to induce anoikis resistance. For this, we overexpressed mouse Id2 in MCF7 wild type cells and quantified apoptosis in suspension cultures using FACS. Interestingly, Id2 overexpression induced a modest but significant 15% reduction of cells undergoing anoikis after 96 h. which was accompanied by a reduction in RBS807/811 phosphorylation levels (Supplementary Fig. 3A, B).
Our data thus show that Id2 is essential for anoikis resistance in E-cadherin mutant ILC cells, and suggest that Id2 is sufficient sustain partial anoikis resistance in E-cadherin expressing cells.
Id2 is a p120-responsive Kaiso target gene in E-cadherin deficient breast cancer cells
Our previous studies had identified Id2 as a candidate Kaiso target gene due to the presence of canonical Kaiso binding sites (cKBS; TCCTGCNA) in mouse Id2 . Further analysis confirmed the presence of a cKBS in human promotor sequences (−500bp to +100 bp) (Fig. 4A). Chromatin immunoprecipitation (ChIP) assays using monoclonal Kaiso antibodies combined with an Id2-specific PCR confirms that Id2 is a Kaiso target gene in mouse and human E-cadherin deficient breast cancer cells (mILC-1 and MDA-MB231) (Fig. 4B). We next cloned approximately 1 kb of the endogenous mouse Id2 promoter (Id2-pro1036)  upstream of a mCherry expression cassette to test promotor activity under anchorage-independent conditions. Using mouse syngeneic (Trp53∆ versus mILC-1) and isogenic human MCF7 cells (WT versus ∆CDH1) models, we observe that loss of E-cadherin increases Id2 reporter activity when transferring cells to anchorage independent conditions (Sus; Fig. 4C, D). Using a luciferase-based Id2 reporter construct transfected into HEK293T cells, we show that transcriptional Id2 responses are reduced 2-fold by exogenous Kaiso expression (Fig. 4E). We also observe an approximate 3-fold increase in Id2-specific reporter activity upon co-expression of p120-1A (Fig. 4E), indicating that Id2 transcription is de-repressed by nuclear p120/Kaiso complex. Moreover, DOX-inducible p120-specific knockdown (p120-iKD) leads to an approximate 3-fold decrease in Id2 protein levels (Fig. 4F). Together, these results establish Id2 as a novel and p120-responsive transcriptional Kaiso target on its canonical target site and provide a mechanistic rationale for the Id2-dependent pro-metastatic control over anoikis resistance in E-cadherin mutant breast cancer cells.
Id2 inhibits Rb-dependent cell cycle progression in the absence of anchorage
Because Id2 can modulate cell cycle responses through the Rb pocket proteins [15, 16], we reasoned that upregulation of Id2 promotes viability through a sustained G0/G1 arrest in anchorage independent ILC cells. We therefore performed co-immunoprecipitation studies on lysates from suspended anoikis resistant cells to confirm that Id2 binds hypo-phosphorylated Rb. In line with published data , we could effectively pull-down hypo-phosphorylated Rb with Id2 antibodies (Supplementary Fig. 4A). Unexpectedly, we find that Id2 is mainly localized to the cytoplasm of mILC-1 cells in both adherent and anchorage independent conditions (Supplementary Fig. 4B–E). Therefore, our data suggest that under these conditions, the Id2-Rb interaction prevents phosphorylation of Rb by cyclin-dependent kinases, thereby attenuating cell cycle responses of E-cadherin mutant ILC cells.
We next confirmed the impact of Id2 or Rb knockdown (Supplementary Fig. 5A) on adherent growth using 2D colony formation assays. In full agreement with published results, we observe that Id2 inhibition in mILC cells results in a marked decrease of proliferation under conventional 2D culture conditions (Supplementary Fig. 5B, C). As expected, loss of Rb has no impact on colony formation, as Rb is already in its inactive hyper-phosphorylated form in most adherent cells. Next, we probed if Id2 knockdown (shRNA) influenced cell cycle progression under anchorage-independent culture conditions. Since Id2 knockdown causes a pronounced induction of anoikis in E-cadherin mutant cells (Fig. 3), we were surprised to observe an increase in cycling and apoptotic cells when cultured in suspension (Fig. 5A, B). Knockdown of Id2 results in an approximate 17% expansion of cells in G2/M and S phase that coincides with an apparent paradoxical decrease in the percentage of viable cells (Fig. 5B, C). In contrast, shRNA depletion of Rb induces a modest increase in cycling cells (Fig. 5A, B), but with no significant effect on anchorage-independent viability (Fig. 5C).
Following this, we assessed whether the induction of cell cycle progression in the absence of Id2 was CDK4/6 dependent. Under anchorage-independent conditions, Id2 knockdown cells show an approximate 5-fold increase in Ser 807/811 Rb phosphorylation, an effect that can be largely abolished by culturing cells in the presence of a CDK4/6 inhibitor (Fig. 5D, E). Because the increase in G2/M cells and the reduction of viability coincides with an approximate 3-fold cumulative increase of phospho-γH2AX positive DNA damage foci in Id2-depleted cells in G2/M (Supplementary Fig. 6A, B), we conclude that upregulation of Id2 prevents a replication stress-induced accumulation of DNA damage in suspended cells.
Together, these data show that in E-cadherin mutant lobular breast cancer cells, Id2 binds to hypo-phosphorylated (active) Rb to dampen cell cycle progression. Further upregulation of Id2 under anchorage-independent conditions blocks cell cycle progression, which prevents accumulation of DNA damage and fosters anoikis resistance.
Id2 expression is increased in E-cadherin mutant primary human organoid ILC models
We next employed two primary human metastatic patient-derived organoid (PDO) ILC models to assess anchorage independent Id2 expression in 3D. We compared KCL320, a classical E-cadherin negative ILC PDO model to P008, an E-cadherin positive ILC PDO model that contains a S180Y mutation in CDH1 (Fig. 6A, B). The extracellular CDH1 mutation in P008 is predicted to render a full-length E-cadherin molecule that cannot undergo homotypic interactions in trans, thus leading to loss of cell-cell adhesion (Supplementary Fig. 7). Using immunofluorescence, we confirm that p120-catenin is mostly localized to the cytosol in KCL320, while P008 displays co-localization of E-cadherin and p120-catenin at the plasma membrane (Fig. 6C). E-cadherin localization in P008 is fragmented when compared to E-cadherin in MCF7 (Fig. 6C), a likely consequence of the inability to engage in homotypic interactions that may result in lateral clustering . In line with our findings in breast cancer cell lines (Fig. 2), we observe a 4-fold increase of Id2 mRNA levels in the E-cadherin negative KCL320 upon transfer to anchorage-independence, but not in the E-cadherin expressing ILC PDO P008 (Fig. 6D). We next used CRISPR/Cas9 to knock-out mutant E-cadherin expression from P008 (Fig. 6E) and observe that loss of E-cadherin expression in P008::ΔCDH1 cells does not impact the typical non-coherent ILC-type 3D structures (Fig. 6F). However, transfer of the isogenic P008 and P008::ΔCDH1 PDO models to anchorage independence showed that E-cadherin loss induces a 5-fold increase of Id2 mRNA levels (Fig. 6G). In short, anchorage independent Id2 mRNA upregulation is causally linked to E-cadherin expression in PDO breast cancer models.
Id2 localizes cytoplasmic in invasive lobular breast carcinomas
We next analyzed a cohort of 148 invasive breast cancer samples (Supplementary Table 1) and compared Id2 expression between IDC of no specific subtype (IDC-NST) and ILC using immunohistochemistry (IHC). In line with our data from the primary and cell line ILC models, we observe that ILC has a higher percentage of cases that express Id2 when compared to IDC-NST (Fig. 7A, B; p = 0.003). Analysis of the publicly available TCGA database reveals that Id2 mRNA expression is indeed elevated in ILC when compared to IDC-NST (ERPOS:HER2NEG samples; p < 0.001) (Fig. 7D). As expected, we did not find indications that Id2 expression is prognostic between IDC-NST and ILC when analyzing several publicly available breast cancer datasets (TCGA, METABRIC, Michaut  and Metzger ) (Supplementary Fig. 8). Using a clinical breast cancer tissue microarray (TMA), we analyzed subcellular distribution of Id2 in 148 invasive breast cancers and observe that ILC cases more often display cytosolic Id2 localization compared to IDC-NST (Fig. 7C, p = 0.0004). These clinical findings concur with our in vitro data that Id2 predominantly localizes in the cytoplasm of ILC cells.
In conclusion, loss of E-cadherin induces a p120/Kaiso-dependent upregulation of Id2, a factor that is essential for anchorage independence and binds hypo-phosphorylated Rb in the cytosol, leading to CDK4/6-dependent cell cycle repression in ILC (Fig. 7E).
It is well-established that luminal ER expressing breast cancers tend to relapse with a longer latency than non-luminal tumors . Interestingly, despite the absence of lymph node involvement and presenting smaller low to intermediate grade tumors, patients with luminal breast cancers will develop distant recurrences . Since large human and mouse studies have suggested that breast cancer dissemination is an early event [33, 34], these combined findings strongly indicate that low proliferative and anoikis-resistant cancer cells are at the basis of non-lymphatic dissemination and long-latency relapses. In this study, we employed both human and mouse ILC models as a paradigm to study the mechanism that drives survival of breast cancer cells during periods of sustained proliferative quiescence, because it might be essential for dormancy and long-term relapses of indolent luminal breast cancer. ILC is renowned for harboring all the hallmarks of an indolent systemic disease. First, low grade ILC invades as single non-cohesive cells that are intrinsically anoikis resistant (reviewed in: ). Second, an ILC diagnosis predicts micro-metastasis in breast cancer . Third, ILC tends to present itself at contralateral sites , and examples of metastatic presentation without a primary tumor have been reported [38, 39]. In line with these disease characteristics, our study demonstrates that indolent ILC cells dampen their proliferative responses upon E-cadherin loss through direct transcriptional de-repression of Id2-dependent cell cycle inhibition, thereby sustaining cell viability in suspension. Given that we demonstrate causality in ERPOS and ERNEG models of human and mouse origin, it also indicates that this mechanism operates independent of estrogen receptor function.
High Id2 levels are associated with terminally differentiated mammary cells, coinciding with β-casein expression in the mammary gland at day 12 of pregnancy . In line with this, it was reported that during mammary gland development, nuclear retention of Id2 is essential for homeostatic differentiation . As such, it appears that Id2 is important for inhibition of differentiation and simultaneous activation of proliferation in the context of normal organ development and function. Seminal studies have shown that Id2 can positively control proliferation of many cancer cell types in 2D, i.e. anchorage-dependent conditions [16, 42]. In adherent dividing cells, the vast majority of Rb is in the hyper-phosphorylated state, allowing E2F transcription factors to drive cell cycle progression . The Rb-dependent proliferative functions of Id2 were identified in U2OS cells, where exogenous Id2 overexpression could overcome serum dependency for growth. The group that first reported these findings moreover demonstrated that Id2 depended on its helix-loop-helix domain for binding the E1A/Large T pocket of hypo-phosphorylated Rb , and concluded that this led to an increase in hyper-phosphorylated Rb, driving cell cycle progression . However, because several viral oncoproteins also bind Rb in this pocket, we consider it is more likely that binding of hypo-phosphorylated Rb by cytosolic Id2 in suspended non-proliferative ILC cells hinders initial CDK4/6-dependent phosphorylation of Rb and subsequent progression beyond the G1 restriction point. Conversely, because overexpression of Id2 in attached U2OS cells leads to a seemingly paradoxical observation of increased proliferation that coincides with decreased levels of Cyclin D1 and Cyclin D1/CDK complexes , it is also possible that cell cycle progression in attached cells, and in the presence of high Id2, may be partly independent of Rb binding, or solely dependent on p16INK4A activity .
Our studies demonstrate that loss of E-cadherin leads to a p120/Kaiso-dependent relief of Id2 transcriptional repression, a phenomenon that is enhanced in the absence of anchorage. Although our data fully support the reported binding of Id2 to hypo-phosphorylated Rb, we hypothesize that in anchorage-independent carcinoma cells, formation of the Id2-Rb complex prevents CDK4/6-dependent Rb phosphorylation by retaining or accumulating Rb in its hypo-phosphorylated active form. Supporting this is the fact that loss of Id2 leads to an increase in Rb phosphorylation and the number of cycling cells in ILC cells in suspension cultures. Second, low to intermediate grade ILC is strongly associated with overexpression of Cyclin D1 [46,47,48], a regulatory subunit of G1/S phase transition and entry into the S-phase by the cyclin-dependent kinases CDK4/6. This feature has been a long-standing and enigmatic paradox in breast cancer; how can high expression levels of Cyclin D1 in ILC be united with a low to intermediate grade breast cancer type? In light of this question and our data, we postulate that cytosolic Id2 functions as a CDK4/6 antagonist through binding to hypo-phosphorylated Rb and subsequent dampening of cell cycle progression in ILC cells. In this context, Id2 therefore might function similarly to the small molecule CDK4/6 inhibitors, inducing compensatory upregulation of Cyclin D1. Supporting this are observation that high Cyclin D1 expression levels correlate with long-term prognosis in ILC , and the finding that the CDK4/6 inhibitor abemaciclib induces upregulation of Cyclin D1 in luminal-type ER+ and lobular-type breast cancer cell lines . Also, our findings in the mILC models and other comparable drug response studies using palbociclib , point to the notion that enhanced responses by luminal breast cancer cells are independent of HER2 status and ER function. Overall, we presume that an increase in Id2 levels during ILC anchorage-independence will halt cell cycle progression at G0/G1 and as such promote invasion and dissemination. Subsequent long-term quiescence or dormancy at specific metastatic niches could then be fostered through distinct and as yet unidentified ECM cues that propel high levels of Id2.
In closing, our study provides novel mechanistic insight and a conceptual rationale for the control over indolent proliferation of ILC, cellular quiescence and cycle re-entry upon cell anchorage. We propose that inactivation of E-cadherin, a lobular histology, and cytosolic Id2, should be considered as criteria to include ERNEG and HER2POS ILC patients for clinical CDK4/6 breast cancer intervention trials.
Material and methods
Cell line and organoid cultures
Mouse cell lines Trp53∆-3 and mILC1 (Cdh1∆;Trp53∆) have been generated from mammary tumors that developed in K14cre;Cdh1F/F;Trp53F/F female mice and cultured as described previously . Similarly, mouse cell lines mILC2 and mILC3 were generated from mammary tumors that developed in Wcre;Cdh1F/F;Trp53F/F female mice . 293T, MCF7, SKBR3, MDA-MB 231 and SUM44PE cell lines were obtained from the American Type Culture Collection (ATCC), STR type verified by PCR and cultured as described previously . Generation of E-cadherin knock-out MCF7::∆CDH1 and Trp53∆::∆Cdh1 cells using CRISPR-Cas9 editing has been described previously . Generation of additional cell lines is described in the supplementary methods. Derivation, establishment, and culturing of PDO models KCL320, P008 and P008::ΔCDH1 is described in detail in the supplementary methods.
Antibodies and reagents
The following primary antibodies were used for western blot analysis: monoclonal rabbit Id2 D39E8 (1:1,000; #3431; Cell Signaling Technology), polyclonal rabbit Id2 C-20 (1:1,000; sc-489; Santa Cruz Biotechnology), polyclonal rabbit Rb M-153 (1:1,000; sc-7905; Santa Cruz Biotechnology), rabbit monoclonal phospho-Rb Ser 780 (1:2000; #9307; Cell Signaling Technology), monoclonal rabbit phospho-Rb Ser 807/811 (1:2,000; #9308; Cell Signaling Technology), monoclonal mouse E-cadherin (ECH6; 1:1000; #MSK033; Zytomed); purified mouse p120-Catenin (Clone98; 1;1000; #610134; BD Biosciences), polyclonal rabbit GFP (1:1000; sc-8334; Santa Cruz Biotechnology), and polyclonal goat Akt1 C-20 (1:1,000; sc-1618; Santa Cruz Biotechnology). The following primary antibodies were used for Immunofluorescence (IF): monoclonal rabbit phospho-Rb Ser 807/811 (1:100; #9308; Cell Signaling Technology), polyclonal rabbit Cleaved Caspase-3 (Asp175) (1:50; #9661; Cell Signaling Technology.), monoclonal TRITC-conjugated mouse E-cadherin (clone 36, 1:50; BD560064; BD Biosciences), monoclonal mouse phospho-Histone H2A.X (Ser139) (clone JBW301, 1:1,000; #05-636; EMD Millipore), monoclonal mouse E-cadherin (ECH6; 1:200; #MSK033; Zytomed); purified mouse p120-Catenin (Clone98; 1;200; #610134; BD Biosciences). immunohistochemistry (IHC) antibodies: Monoclonal mouse Id2 (clone OTI10C3; 1:25,000; TA500183; Origene Technologies), Monoclonal rabbit phospho-Rb Ser 807/811 (1:100; #9308; Cell Signaling Technology).
Lentiviral and inducible p120-specific shRNA constructs (p120-iKD) have been described previously . Sequences were verified by Sanger DNA sequencing. Additional cloning methods and primer sequences are described in detail in the supplementary methods.
Id2 reporter assay
HEK 293T cells were cultured and transfected with 100 ng pGL4-Id2pro-1036 and 5 ng pRL-Renilla in combination with either 400 ng empty vector (pcDNA3.1) or pC2-eGFP-p120-1A or pcDNA3.1-Kaiso using XtremeGene9 (Roche) Reporter activity was measured using the Dual-Luciferase Reporter kit (Promega) on a Lumat LB9507 Luminometer (Berthold Technologies) according to manufacturer’s instructions. Cell lines transduced with the Id2-mCherry reporter viruses were cultured in anchorage-independent conditions for the indicated time periods and fluorescence was quantified by flowcytometry using a FACS Celesta (BD Biosciences). Data was processed using the FACSdiva software (Version 8.0) and analyzed in Prism (Version 8.0).
Kaiso Chromatin Immunoprecipitations (ChIP) and PCR
ChIP procedures and PCR were done as previously described . The following primers were used for amplification of the target promoter sequences: mouse Id2: FW; 5′-CAA ATG TGA CTT CCC AAA AGC-3′ and REV; 5′-GCC TTA TTC CAA TTC CCA GA-3′. Human Id2: FW; 5′-AGC CCC GCA CTT ACT GTA CT-3′ and REV; 5′-CTT CCC TTC GTC CCC ATT-3′. The following primer sequences were used as negative control: mouse Id2: FW; 5′ – AGG ATC CCG GTG CCA TAA AC – 3′ and REV5′- CAA CTG CGT GCT CAT TTC CG – 3′. Human Id2: FW; 5′- TGC ATG CAC ACA CAC ACA C – 3′and REV5′- AAG AAA GGC TGG GAC CTG AG – 3′.
Production of lentiviral particles and transduction was performed as previously described .
IHC was carried out on 4 µm thick tissue sections as described previously . Detailed description of Id2 IHC scoring can be found in the supplementary methods.
Statistical tests were performed in Microsoft Excel and GraphPad Prism 8 using Student t tests assuming non-gaussian distributions. Unless stated differently, a minimum of three independent experiments, with three biological replicates, were considered. Error bars show either standard deviation (SD) or standard error of the mean (SEM), as stated in the figure legend. Western blots were quantified using ImageJ, converting pixel intensity to white/black scales and normalized to loading controls. Statistical test on the clinical tissue micro array of invasive breast cancer was performed using IBM SPSS Statistics version 188.8.131.52. Associations between categorical variables were calculated using the 369 Pearson’s Chi-square test. P-values <0.05 were considered statistically significant. For the bioinformatics analysis, Wilcoxon Rank tests were performed. Violin plots were generated using GraphPad Prism 8.
Additional experiments procedures regarding anoikis resistance and FACS analysis, RNA sequencing, co-immunoprecipitations, RT-qPCR, colony formation assays, lung colonization assays, immunofluorescence microscopy, and analysis of human expression data are available in the supplementary information [56,57,58,59,60,61,62,63,64,65,66,67].
Mathieu M-C, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer. 2004;40:342–51.
Guiu S, Wolfer A, Jacot W, Fumoleau P, Romieu G, Bonnetain F, et al. Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions? Critical Rev Oncol Hematol. 2014;92:235–57.
Berx G, Cleton-Jansen AM, Nollet F, Leeuw WJD, Vijver MV, Cornelisse C. et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 1995;14:6107–15.
Derksen PWB, Liu X, Saridin F, Gulden HVD, Zevenhoven J, Evers B, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 2006;10:437–49.
Meng W, Takeichi M. Adherens junction: molecular architecture and regulation. Cold Spring Harb Perspect Biol. 2009;1:a002899.
Boelens MC, Nethe M, Klarenbeek S, Ruiter JRde, Schut E, Bonzanni N, et al. PTEN loss in E-cadherin-deficient mouse mammary epithelial cells rescues apoptosis and results in development of classical invasive lobular carcinoma. Cell Rep. 2016;16:2087–101.
Annunziato S, Kas SM, Nethe M, Yücel H, Bravo JD, Pritchard C, et al. Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. Genes Dev. 2016;30:1470–80.
Christgen M, Cserni G, Floris G, Marchio C, Djerroudi L, Kreipe H, et al. Lobular breast cancer: histomorphology and different concepts of a special spectrum of tumors. Cancers. 2021;13:3695.
Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6:R149–56.
Desmedt C, Zoppoli G, Sotiriou C, Salgado R. Transcriptomic and genomic features of invasive lobular breast cancer. Seminars Cancer Biol. 2017;44:98–105.
Bruner HC, Derksen PWB. Loss of E-cadherin-dependent cell-cell adhesion and the development and progression of cancer. Csh Perspect Biol. 2018;10.
Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008;26:3006–14.
Korhonen T, Kuukasjärvi T, Huhtala H, Alarmo EL, Holli K, Kallioniemi A, et al. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. Breast. 2013;22:1119–24.
Johnson J, Thijssen B, McDermott U, Garnett M, Wessels LFA, Bernards R. Targeting the RB-E2F pathway in breast cancer. Oncogene. 2016;35:4829–35.
Iavarone A, Garg P, Lasorella A, Hsu J, Israel MA. The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein. Genes Dev. 1994;8:1270–84.
Lasorella A, Iavarone A, Israel MA. Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins. Mol Cell Biol. 1996;16:2570–8.
Coma S, Amin DN, Shimizu A, Lasorella A, Iavarone A, Klagsbrun M. Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F. Cancer Res. 2010;70:3823–32.
Rollin J, Bléchet C, Régina S, Tenenhaus A, Guyétant S, Gidrol X. The intracellular localization of ID2 expression has a predictive value in non small cell lung cancer. PLoS One. 2009;4:e4158.
Gray MJ, Dallas NA, Buren GV, Xia L, Yang AD, Somcio RJ, et al. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene. 2008;27:7192–7200.
Zhou J-D, Ma J-C, Zhang T-J, Li X-X, Zhang W, Wu D-H, et al. High bone marrow ID2 expression predicts poor chemotherapy response and prognosis in acute myeloid leukemia. Oncotarget. 2017;8:91979–89.
Wazir U, Jiang WG, Sharma AK, Newbold RF, Mokbel K. The mRNA expression of inhibitors of DNA binding-1 and -2 is associated with advanced tumour stage and adverse clinical outcome in human breast cancer. Anticancer Res. 2013;33:2179–83.
Kijewska M, Viski C, Turrell F, Fitzpatrick A, Weverwijk Avan, Gao Q, et al. Using an in-vivo syngeneic spontaneous metastasis model identifies ID2 as a promoter of breast cancer colonisation in the brain. Breast Cancer Res. 2019;21:4.
Liu Y, Pandey PR, Sharma S, Xing F, Wu K, Chittiboyina A, et al. ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness. Breast Cancer Res Treatment. 2019;175:77–90.
Teo K, Gómez-Cuadrado L, Tenhagen M, Byron A, Rätze M, van Amersfoort M, et al. E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer. Sci Rep. 2018;8:15454.
Derksen PWB, Braumuller TM, van der Burg E, Hornsveld M, Mesman E, Wesseling J, et al. Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. Dis Model Mech. 2011;4:347–58.
Ven RAHvande, Tenhagen M, Meuleman W, Riel JJGvan, Schackmann RCJ, Derksen PWB. Nuclear p120-catenin contributes to anoikis resistance of Lobular Breast Cancer through Kaiso-dependent Wnt11 expression. Dis Model Mech. 2015;8:373–84.
Li H, Ji M, Klarmann KD, Keller JR. Repression of Id2 expression by Gfi-1 is required for B-cell and myeloid development. Blood. 2010;116:1060–9.
Troyanovsky RB, Sokolov E, Troyanovsky SM. Adhesive and lateral E-cadherin dimers are mediated by the same interface. Mol Cell Biol. 2003;23:7965–72.
Michaut M, Chin S-F, Majewski I, Severson TM, Bismeijer T, Koning Lde, et al. Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Sci Rep. 2016;6:18517.
Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, et al. Genomic grade adds prognostic value in invasive lobular carcinoma. Ann Oncol. 2013;24:377–84.
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.
Engel J, Eckel R, Kerr J, Schmidt M, Fürstenberger G, Richter R, et al. The process of metastasisation for breast cancer. EurJCancer. 2003;39:1794–806.
Husemann Y, Geigl J, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13:58–68.
Christgen M, Steinemann D, Kühnle E, Länger F, Gluz O, Harbeck N, et al. Lobular breast cancer: clinical, molecular and morphological characteristics. Pathol Res Pract. 2016;212:583–97.
Gainer SM, Lodhi AK, Bhattacharyya A, Krishnamurthy S, Kuerer HM, Lucci A. Invasive lobular carcinoma predicts micrometastasis in breast cancer. J Surg Res. 2012;177:93–96.
Newstead GM, Baute PB, Toth HK. Invasive lobular and ductal carcinoma: mammographic findings and stage at diagnosis. Radiology. 1992;184:623–7.
Engelstaedter V, Mylonas I. Lower genital tract metastases at time of first diagnosis of mammary invasive lobular carcinoma. Arch Gynecol Obstetrics. 2011;283:93–95.
Proença RP, Fernandes J, Burnier MN, Proença R. Orbital metastasis from an occult breast carcinoma (T0, N1, M1). BMJ Case Rep. 2018;2018:bcr-2017-223542.
Parrinello S, Lin CQ, Murata K, Itahana Y, Singh J, Krtolica A, et al. Id-1, ITF-2, and Id-2 comprise a network of helix-loop-helix proteins that regulate mammary epithelial cell proliferation, differentiation, and apoptosis. J Biol Chem. 2001;276:39213–9.
Kim N-S, Kim H-T, Kwon M-C, Choi S-W, Kim Y-Y, Yoon K-J, et al. Survival and differentiation of mammary epithelial cells in mammary gland development require nuclear retention of Id2 due to RANK signaling. Mol Cell Biol. 2011;31:4775–88.
Meng Y, Gu C, Wu Z, Zhao Y, Si Y, Fu X, et al. Id2 promotes the invasive growth of MCF-7 and SKOV-3 cells by a novel mechanism independent of dimerization to basic helix-loop-helix factors. BMC Cancer. 2009;9:75.
Manning AL, Dyson NJ. RB: mitotic implications of a tumour suppressor. Nat Rev Cancer. 2012;12:220–6.
Kaelin WG, Pallas DC, DeCaprio JA, Kaye FJ, Livingston DM. Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell. 1991;64:521–32.
Shapiro GI, Edwards CD, Rollins BJ. The physiology of p16(INK4A)-mediated G1 proliferative arrest. Cell Biochem Biophys. 2000;33:189–97.
Diest PJvan, Michalides RJ, Jannink L, Valk Pvander, Peterse HL, Jong JSde, et al. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol. 1997;150:705–11.
Oyama T, Kashiwabara K, Yoshimoto K, Arnold A, Koerner F. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res. 1998;58:2876–80.
Jares P, Rey MJ, Fernández PL, Campo E, Nadal A, Muñoz M, et al. Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status. J Pathol. 1997;182:160–6.
Tobin NP, Lundgren KL, Conway C, Anagnostaki L, Costello S, Landberg G. Automated image analysis of cyclin D1 protein expression in invasive lobular breast carcinoma provides independent prognostic information. Human Pathol. 2012;43:2053–61.
O’Brien N, Conklin D, Beckmann R, Luo T, Chau K, Thomas J, et al. Preclinical activity of abemaciclib alone or in combination with antimitotic and targeted therapies in breast cancer. Mol Cancer Therapeutics. 2018;17:897–907.
Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.
Schackmann RCJ, van Amersfoort M, Haarhuis JHI, Vlug EJ, Halim VA, Roodhart JML, et al. Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. J Clin Invest. 2011;121:3176–88.
Hornsveld M, Tenhagen M, van de Ven RA, Smits AMM, van Triest MH, van Amersfoort M, et al. Restraining FOXO3-dependent transcriptional BMF activation underpins tumour growth and metastasis of E-cadherin-negative breast cancer. Cell Death Differ. 2016;23:1483–92.
Pierre CC, Longo J, Bassey-Archibong BI, Hallett RM, Milosavljevic S, Beatty L, et al. Methylation-dependent regulation of hypoxia inducible factor-1 alpha gene expression by the transcription factor Kaiso. Biochim Biophys Acta. 2015;1849:1432–41.
Vlug EJ, van de Ven RAH, Vermeulen JF, Bult P, van Diest PJ, Derksen PWB. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol. 2013;36:375–84.
Di Z, Klop MJD, Rogkoti V-M, Dévédec SEL, van de Water B, Verbeek FJ. et al. Ultra high content image analysis and phenotype profiling of 3D cultured micro-tissues. PLoS ONE. 2014;9:e109688.
Sandercock AM, Rust S, Guillard S, Sachsenmeier KF, Holoweckyj N, Hay C, et al. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling. Mol Cancer. 2015;14:147–18.
Booij TH, Klop MJD, Yan K, Szántai-Kis C, Szokol B, Orfi L, et al. Development of a 3D tissue culture-based high-content screening platform that uses phenotypic profiling to discriminate selective inhibitors of receptor tyrosine kinases. J Biomol Screen. 2016;21:912–22.
Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell. 2008;132:487–98.
Herold MJ, van den Brandt J, Seibler J, Reichardt HM. Indu cible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats. Proc Natl Acad Sci. 2008;105:18507–12.
Mandoli A, Prange K, Martens JHA. Genome-wide binding of transcription factors in inv(16) acute myeloid leukemia. GDATA. 2014;2:170–2.
Suzuki K, Bose P, Leong-Quong RY, Fujita DJ, Riabowol K. REAP: a two minute cell fractionation method. BMC Res Notes. 2010;3:294.
Schackmann RCJ, Klarenbeek S, Vlug EJ, Stelloo S, van Amersfoort M, Tenhagen M, et al. Loss of p120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signaling. Cancer Res. 2013;73:4937–49.
Pereira B, Chin S-F, Rueda OM, Vollan H-KM, Provenzano E, Bardwell HA, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479.
Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1–pl1.
Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41:D991–5.
We thank Jonathan R. Keller (National Cancer Institute, Frederick, MA, USA) for the Id2 reporter, and Livio Kleij and Nikki Kolsters for technical support. Members from the De Bruin and Daniel laboratories are acknowledged for input and fruitful discussions. We thank the UMC Utrecht Cell Microscopy Center for imaging support. Rebecca Marlow and Eleanor Knight (BCN Organoid Facility) for their advice on the ILC PDO generation and Angela Clifford (KCL) in her role as BTBC trial coordinator. We acknowledge NHS funding to the NIHR Biomedical Research Centres at both Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, and the Royal Marsden NHS Foundation Trust and the Canadian Breast Cancer Foundation, the Juravinski Hospital and Cancer Center Foundation (JHCCF). BIB-A was partly supported by a Schlumberger Faculty for the Future Fellowship. We received financial support by Breast Cancer Now (CTR-Q4-Y3), NC3Rs (NC/P001262/1) (CMI/AT) and a Medical Research Council Clinical Research Training Fellowship (AF), grants from the Netherlands Organization for Scientific Research (NWO/ZonMW-VIDI 016.096.318), the Dutch Cancer Society (KWF-UU-2011-5230, KWF-UU-2014-7201 and KWF-UU-2016-10456), Breast Cancer Now (2018NovPCC1297) which is supported by funding from Pfizer, and the European Union’s Horizon 2020 FET Proactive program under the grant agreement No. 731957 (MECHANO-CONTROL). This publication is based upon work from COST action LOBSTERPOT (CA19138), supported by COST (European Cooperation in Science and Technology).
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Rätze, M.A.K., Koorman, T., Sijnesael, T. et al. Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer. Oncogene 41, 2932–2944 (2022). https://doi.org/10.1038/s41388-022-02314-w